SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.
Also called NCT05782192
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 458 participants
- Registry
-
NCT05782192
-
- Other papers using this trial's data
- Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05782192. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-13 (actual); primary completion 2022-03-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- SAL067
- Intervention (Drug)
- Alogliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Record details
- Record id
cardio:ct-nct05782192- Content hash
f18e64416c9341e06e2eb04df38bd91458f95b7ebdd3f6d95240270979bff47a